According to the FAM molecular subtypes, we have identified 6 FAMRGs (ACLS5, PLA2G2D, PROCA1, IL4I1, UBE2L6) that could significantly contribute to the response of HNSCC patients undergoing anti‐PD1 therapy. This evidence concerns the gene USP9X and head and neck squamous cell carcinoma.